vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $196.0M, roughly 1.8× Axsome Therapeutics, Inc.). AdvanSix Inc. runs the higher net margin — -0.8% vs -14.6%, a 13.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ASIX vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $196.0M |
| Net Profit | $-2.8M | $-28.6M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | -13.8% |
| Net Margin | -0.8% | -14.6% |
| Revenue YoY | 9.4% | 65.0% |
| Net Profit YoY | -892.9% | 61.9% |
| EPS (diluted) | $-0.11 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $196.0M | ||
| Q3 25 | $374.5M | $171.0M | ||
| Q2 25 | $410.0M | $150.0M | ||
| Q1 25 | $377.8M | $121.5M | ||
| Q4 24 | $329.1M | $118.8M | ||
| Q3 24 | $398.2M | $104.8M | ||
| Q2 24 | $453.5M | $87.2M | ||
| Q1 24 | $336.8M | $75.0M |
| Q4 25 | $-2.8M | $-28.6M | ||
| Q3 25 | $-2.6M | $-47.2M | ||
| Q2 25 | $31.4M | $-48.0M | ||
| Q1 25 | $23.3M | $-59.4M | ||
| Q4 24 | $352.0K | $-74.9M | ||
| Q3 24 | $22.3M | $-64.6M | ||
| Q2 24 | $38.9M | $-79.3M | ||
| Q1 24 | $-17.4M | $-68.4M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | -13.8% | ||
| Q3 25 | -0.9% | -27.0% | ||
| Q2 25 | 7.7% | -24.5% | ||
| Q1 25 | 7.7% | -46.9% | ||
| Q4 24 | -3.9% | -61.1% | ||
| Q3 24 | 7.5% | -59.8% | ||
| Q2 24 | 11.5% | -89.5% | ||
| Q1 24 | -7.0% | -89.7% |
| Q4 25 | -0.8% | -14.6% | ||
| Q3 25 | -0.7% | -27.6% | ||
| Q2 25 | 7.7% | -32.0% | ||
| Q1 25 | 6.2% | -48.9% | ||
| Q4 24 | 0.1% | -63.1% | ||
| Q3 24 | 5.6% | -61.7% | ||
| Q2 24 | 8.6% | -91.0% | ||
| Q1 24 | -5.2% | -91.1% |
| Q4 25 | $-0.11 | $-0.55 | ||
| Q3 25 | $-0.10 | $-0.94 | ||
| Q2 25 | $1.15 | $-0.97 | ||
| Q1 25 | $0.86 | $-1.22 | ||
| Q4 24 | $0.02 | $-1.54 | ||
| Q3 24 | $0.82 | $-1.34 | ||
| Q2 24 | $1.43 | $-1.67 | ||
| Q1 24 | $-0.65 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $88.3M |
| Total Assets | $1.7B | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $322.9M | ||
| Q3 25 | $23.7M | $325.3M | ||
| Q2 25 | $18.4M | $303.0M | ||
| Q1 25 | $8.3M | $300.9M | ||
| Q4 24 | $19.6M | $315.4M | ||
| Q3 24 | $17.3M | $327.3M | ||
| Q2 24 | $12.1M | $315.7M | ||
| Q1 24 | $20.6M | $331.4M |
| Q4 25 | $815.2M | $88.3M | ||
| Q3 25 | $818.2M | $73.7M | ||
| Q2 25 | $823.7M | $73.1M | ||
| Q1 25 | $794.4M | $53.2M | ||
| Q4 24 | $774.6M | $57.0M | ||
| Q3 24 | $766.4M | $92.9M | ||
| Q2 24 | $746.6M | $102.9M | ||
| Q1 24 | $713.2M | $144.0M |
| Q4 25 | $1.7B | $689.8M | ||
| Q3 25 | $1.7B | $669.3M | ||
| Q2 25 | $1.6B | $639.8M | ||
| Q1 25 | $1.6B | $596.7M | ||
| Q4 24 | $1.6B | $568.5M | ||
| Q3 24 | $1.5B | $561.5M | ||
| Q2 24 | $1.5B | $548.2M | ||
| Q1 24 | $1.5B | $545.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $-18.7M |
| Free Cash FlowOCF − Capex | $36.1M | $-18.7M |
| FCF MarginFCF / Revenue | 10.0% | -9.6% |
| Capex IntensityCapex / Revenue | 7.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $-18.7M | ||
| Q3 25 | $26.6M | $1.0M | ||
| Q2 25 | $21.1M | $-32.4M | ||
| Q1 25 | $11.4M | $-43.4M | ||
| Q4 24 | $64.2M | $-26.2M | ||
| Q3 24 | $57.3M | $-18.6M | ||
| Q2 24 | $50.2M | $-30.1M | ||
| Q1 24 | $-36.2M | $-53.5M |
| Q4 25 | $36.1M | $-18.7M | ||
| Q3 25 | $66.0K | $988.0K | ||
| Q2 25 | $-7.2M | $-32.4M | ||
| Q1 25 | $-22.6M | $-43.7M | ||
| Q4 24 | $29.8M | $-26.2M | ||
| Q3 24 | $26.8M | $-18.7M | ||
| Q2 24 | $16.7M | $-30.2M | ||
| Q1 24 | $-71.6M | $-53.6M |
| Q4 25 | 10.0% | -9.6% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | -1.7% | -21.6% | ||
| Q1 25 | -6.0% | -36.0% | ||
| Q4 24 | 9.1% | -22.1% | ||
| Q3 24 | 6.7% | -17.9% | ||
| Q2 24 | 3.7% | -34.6% | ||
| Q1 24 | -21.3% | -71.4% |
| Q4 25 | 7.7% | 0.0% | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 6.9% | 0.0% | ||
| Q1 25 | 9.0% | 0.3% | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | 7.7% | 0.1% | ||
| Q2 24 | 7.4% | 0.1% | ||
| Q1 24 | 10.5% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
AXSM
Segment breakdown not available.
